FDA Center for Tobacco Products Complaint Regarding Retailer Violation
The FDA Center for Tobacco Products (CTP) filed a complaint (FDA-2026-H-3866-0001) on April 14. The complaint relates to potential violations of federal tobacco product regulations, specifically concerning retailer compliance with sales and marketing requirements. The document represents a formal complaint filing within the FDA's regulatory enforcement process.
Complaint Filed by Center for Tobacco Products
The FDA Center for Tobacco Products (CTP) filed a complaint with tracking number FDA-2026-H-3841. The complaint was submitted on April 14 and is now accessible via regulations.gov. Only a PDF attachment of the complaint is available for download; no summary documents are viewable on the regulatory portal.
B.E. Meyers & Co. Variance Application - CDRH
B.E. Meyers & Co., Inc. has submitted a variance application to the FDA Center for Devices and Radiological Health (CDRH). The application requests permission to deviate from specific regulatory requirements applicable to the company's medical device operations. FDA has received and posted the application for public access via Regulations.gov under docket FDA-2025-V-4733-0001.
Variance Application, Christ The King Lutheran Church, FDA, North Carolina
Christ The King Lutheran Church in North Carolina submitted a variance application to the FDA Center for Devices and Radiological Health (CDRH) under docket FDA-2026-V-3505. The specific regulatory requirements or medical device standards at issue are not disclosed in the available metadata. No documents are currently available for public review on Regulations.gov.
Background Material for Docket FDA-2026-P-4022
FDA published background material under docket FDA-2026-P-4022 on April 14. The document contains supporting information related to a regulatory matter before the agency. No specific regulatory requirements, compliance deadlines, or penalties are stated in the available filing.
Variance Amendment - SRS Visual, CDRH
FDA's Center for Devices and Radiological Health (CDRH) issued a variance amendment related to SRS Visual. The variance was filed under docket FDA-2026-V-2145. The specific regulatory requirements being modified and the scope of the variance cannot be determined from available metadata as the full document content is not accessible.
Good Brain Tonic Recalled by Liquid Blenz Corp Due to Botulism Risk
Liquid Blenz Corp of Rockville Center, NY is recalling all codes of Good Brain Tonic (16 oz and 32 oz amber bottles) due to potential botulism contamination. The contamination was discovered through analysis by Cornell Food Venture Center and field testing by New York State Department of Agriculture and Markets Food Inspectors. The product was distributed nationwide through retail stores and internet sales. No illnesses have been reported to date.
Nucleic Acid Complexes with Cationic/Anionic Polymers and RNA Molecules
The USPTO published patent application US20260096998A1 for nucleic acid complexes comprising cationic polymers, anionic polymers, and monomeric RNA molecules. The disclosed complexes feature a core structure where the cationic polymer and RNA molecule are encapsulated by the anionic polymer. The application covers linear and non-linear configurations of these complexes for therapeutic uses.
Thraustochytrids, Fatty Acid Compositions, and Methods - DSM Assets
USPTO published patent application US20260096578A1 by DSM IP Assets B.V. covering isolated thraustochytrid microorganisms, microbial oils, biomasses, compositions, and associated production and use methods. The application, filed August 13, 2025, lists six inventors and covers CPC classifications spanning food, cosmetic, and pharmaceutical applications.
Microbial Compositions and Methods for Fermented Foods
USPTO published patent application US20260096563A1 for microbial compositions comprising purified populations of microorganisms used in producing dough or baked food products. The compositions are designed to enhance fermentation by improving rheological properties, nutritional quality, and shelf-life of dough and baked food products. The application was filed on December 9, 2025, with inventors Cameron Martino and James Gaffney.
TUV SUD America OSHA Recognition Expansion
OSHA is seeking public comments on expanding the OSHA recognition of TUV SUD America as a Nationally Recognized Testing Laboratory (NRTL). TUV SUD America is seeking to add additional test standards to its existing OSHA recognition. Interested parties may submit comments on whether the expansion should be approved. The comment deadline is April 29.
TÜV SÜD America NRTL Scope Expansion, Comments Due April 29
OSHA announces TÜV SÜD America, Inc. (TUVAM) application for expansion of its Nationally Recognized Testing Laboratory (NRTL) scope of recognition to include one additional test site. The agency presents its preliminary finding to grant the expansion and seeks public comments on the application. Comments are due April 29, 2026.
Intraocular Lens Podeye Safety Notice - Field Safety Notice R2610293
ANSM has informed health establishments of a safety action implemented by the company Physiol/BVI regarding Podeye intraocular lenses. The safety action is registered under reference number R2610293. Health establishments concerned by this action should review the attached letter from Physiol/BVI dated 14/04/2026.
Inova Diagnostics Aptiva CTD Essential Controls Safety Action
ANSM published safety alert R2608798 informing medical biology laboratories of a quality control recall by Inova Diagnostics for Aptiva CTD Essential Controls used in autoimmune testing. The manufacturer's safety action letter was distributed to affected users on 14 April 2026. Laboratories should review the recalled controls and contact Inova Diagnostics directly for guidance.
Biomarker Combinations for NASH and Hepatic Fibrosis Diagnosis
USPTO granted patent US12601747B2 to Bio-Rad Laboratories for biomarker combinations used to diagnose Non-Alcoholic Steatohepatitis (NASH) and hepatic fibrosis status. The patent covers methods and kits for evaluating liver conditions based on three or more biomarker levels in subjects with NAFLD or NASH.
Maize Gene KRN2 and Uses Thereof Patent Grant US12600976B2
The USPTO granted Patent US12600976B2 to China Agricultural University for KRN2 gene technology controlling kernel row number in maize plants and associated molecular markers for molecular breeding applications. The patent contains 6 claims and names six inventors including Xiaohong Yang, Jiansheng Li, Wenkang Chen, Xuan Zhang, Lichun Cai, and Yirong Zhang.
Treating Glioblastoma Using Integrin Pathway Targeting
USPTO granted patent US12601743B2 to The Regents of the University of California for methods of treating drug-resistant glioblastoma (GBM) by targeting the integrin avb3 pathway. The patent covers diagnostic methods to determine tumor sensitivity and treatment methods for tumors identified as avb3+ and Glut3+ with specific molecular signatures. The patent contains 9 claims.
National Nutrition Committee Holds Fourth Meeting in Riyadh
The National Nutrition Committee held its fourth meeting of the third session at SFDA headquarters in Riyadh, chaired by SFDA CEO H.E. Dr. Hisham S. Aljadhey. The Committee reviewed its strategic performance report covering initiatives, projects, and achievements through Q1 2026, as well as the Saudi Food Composition Tables book developed under the Nutrient Content of Foods initiative. The meeting included representatives from various government and private sector entities.
Medicare HCPCS Level II Public Meeting
CMS announces the first biannual 2026 HCPCS Level II public meeting to discuss preliminary coding, Medicare benefit category, and payment determinations for new non-drug and non-biological items and services. The primary meeting is scheduled for June 1, 2026 in Baltimore, MD, with an overflow virtual session on June 2, 2026. Speaker registration closes May 18, 2026, and written comments are due June 3, 2026.
Electronic Prior Authorization Requirements for Medicare Advantage Medicaid CHIP QHP Issuers
CMS published a proposed rule (CMS-0062-P) requiring Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the Federally-facilitated Exchanges to implement electronic prior authorization for drugs and extend existing interoperability requirements to drugs. The rule would also require impacted payers to report API endpoints to CMS, adopt HL7 FHIR standards as HIPAA transaction standards, and would establish a definition for "failure to report" enabling civil monetary penalties for applicable manufacturers or GPOs that fail to grant CMS timely access for audits. Comments are due June 15, 2026.
Merit Medical Recalls 16F Dual-Valved Splittable Sheath Introducer
Merit Medical is recalling the 16F Dual-Valved Splittable Sheath Introducer, a component used in several dialysis catheter kits, due to a design defect where the sheath introducer may not split as intended. The FDA has classified this as a Class I recall, the most serious type. Healthcare providers are advised to immediately stop using, apply recall stickers to, and destroy affected devices. Two serious injuries have been reported as of February 23, 2026, with no deaths associated with this issue.
5T4 Binding Polypeptides for Cancer Therapy
USPTO granted patent US12600794B2 to Abdera Therapeutics for 5T4 binding polypeptides useful for cancer therapy. The 36 claims cover polypeptides conjugated to chelating agents or radionuclide complexes. The patent protects compositions and methods for treating 5T4-expressing cancers.
IGF-1R Antibodies With Extended Half-Lives for Thyroid Eye Disease Treatment
USPTO granted US Patent US12600788B2 to Viridian Therapeutics, Inc. covering antibodies and compositions targeting Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives for treating thyroid eye disease. The patent contains 18 claims and names six inventors including Vahe Bedian, Peter Harwin, and Jonathan Violin.
Single-Domain Antibodies That Bind ROR1
USPTO granted Patent US12600801B2 to Fred Hutchinson Cancer Center for single-domain antibodies binding receptor tyrosine kinase ROR1. The patent covers anti-cancer therapeutics, antibody-drug conjugates, multi-domain binding molecules, and cancer imaging/diagnostic agents. The patent contains 20 claims with inventors Jason Price, Colin E. Correnti, and James M. Olson.
Anti-IgG Nanobodies Patent Granted to Max-Planck
USPTO granted patent US12600799B2 to Max-Planck-Gesellschaft on April 14, 2026 for novel anti-IgG nanobodies directed against rabbit or mouse IgG. The patent contains 11 claims classified under CPC C07K 16/42. The invention also covers methods for producing and using said nanobodies.
CD38 Antibody Variant Improves Manufacturing Yield
USPTO granted patent US12600790B2 to Vivasor, Inc. covering a variant anti-CD38 IgG antibody with improved manufacturing yield and a mutated light chain that reduces cleavage heterogeneity. The patent contains 19 claims and is classified under C07K 16/2878 and related CPC codes.
TB Follow-up Worksheet, Newly-Arrived Deadline 14th Jun
CDC has published a TB Follow-up Worksheet for newly-arrived individuals with a compliance deadline of June 14th. The worksheet provides guidance for TB screening follow-up procedures for newly-arrived populations. Healthcare providers and public health authorities conducting TB screening should utilize this document for compliance purposes.
NCHS Data Detectives Camp, Comments Due Jun 14
CDC's National Center for Health Statistics (NCHS) is seeking public comments on the NCHS Data Detectives Camp educational program. The program is designed to educate students about health statistics and data analysis. Comments are due June 14.
Prospective Grant of Exclusive Patent License: Catheter-Based Myotomy Devices And Systems
The National Institutes of Health (NIH) has published a notice of prospective grant of exclusive patent license to Septune for catheter-based myotomy devices and systems. The NIH is seeking public comments on this prospective license agreement. The comment period closes on May 14, 2026.
National Institute of Dental and Craniofacial Research Notice of Closed Meeting
The National Institute of Dental and Craniofacial Research (NIDCR) has issued a notice announcing a closed advisory council meeting scheduled for May 27-28, 2026. The meeting is closed to the public as it will involve discussion of grant applications and other privileged or predecisional matters. This is a routine administrative announcement.
National Heart, Lung, and Blood Institute Notice of Meeting
The National Heart, Lung, and Blood Institute (NHLBI), part of the NIH, published a Federal Register Notice on April 14, 2026 announcing a public meeting scheduled for May 26, 2026. This notice satisfies requirements under the Federal Advisory Committee Act for public disclosure of advisory committee meetings. No regulatory obligations or compliance deadlines are established by this document.
Federal Register Daily Issue, 14th Apr
The Federal Register published its daily issue on April 14, 2026, containing 112 documents from 38 agencies across 1006 pages. The issue includes 95 Notices, 8 Proposed Rules, and 9 Rules, along with 3 Significant Documents. This table of contents provides access to documents from agencies including the Air Force Department, Centers for Disease Control and Prevention, and Agriculture Department.
Draft Guidance on Safety Assessment of Genome Editing Using Next-Generation Sequencing
The FDA's Center for Biologics Evaluation and Research issued draft guidance recommending next-generation sequencing methods for assessing off-target editing risks and genome integrity in human gene therapy products using genome editing technologies. The guidance applies to both ex vivo and in vivo products and provides recommendations on sequencing strategies, sample selection, analysis parameters, and reporting. Sponsors submitting investigational new drug applications or Biologics License Applications for genome editing therapies should incorporate these safety assessment methods into nonclinical studies. The FDA is accepting public comments for 90 days.
LAG-3 Antibody Combination Therapies - Patent US12600777B2
The USPTO granted patent US12600777B2 to Novartis AG covering combination therapies comprising antibody molecules that specifically bind to LAG-3. The patent contains seven claims and relates to methods for treating, preventing, and/or diagnosing cancerous or infectious disorders. This represents a grant of exclusive intellectual property rights to Novartis AG for the therapeutic application of LAG-3 antibody combinations.
RAGE Antibodies Patent Granted SUNY Apr 14
USPTO granted Patent US12600778B2 to The Research Foundation for The State University of New York for antibodies specific to the heparan sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE). The patent includes methods for treating conditions involving RAGE through antibody administration, with 4 claims allowed.
Tumor-Targeted Bispecific CD28 Antigen Binding Molecules Patent Grant
USPTO granted patent US12600781B2 to Hoffmann-La Roche Inc. covering tumor-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28. The patent includes 51 claims covering the binding molecules, methods of production, pharmaceutical compositions containing these antibodies, and methods of using the same for cancer treatment.
Method of Screening Compounds Inhibiting Pancreatic Cancer RNF43 Mutation
The USPTO granted Patent US12600785B2 to Antlera Therapeutics Inc. covering a method of screening compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene. The patent discloses FZD5-binding agents for treating diseases associated with aberrant Frizzled protein expression. The patent contains 5 claims and names Guohua Pan, Jason Moffat, Sachdev Sidhu, Stephane Angers, Zachary Steinhart, and Xiaowei Wang as inventors.
Novo Nordisk Patent for IL-6 Antagonist Treatment of Diuretic Resistant Heart Failure
The USPTO granted Patent US12600773B2 to Novo Nordisk A/S on April 14, 2026, covering methods of treating diuretic resistant heart failure patients carrying at least one copy of the TMPRSS6 rs855791 allele by administering an IL-6 antagonist. The patent also covers treatment of patients with elevated urine or plasma IL-6 levels requiring diuresis. The patent (CPC: C07K 16/248) names five inventors and issues from Application No. 17519082 filed November 4, 2021, with 10 claims granted.
CDC Agency Forms Undergoing Paperwork Reduction Act Review
CDC has submitted the information collection request "Poison Center Collaborations for Public Health Emergencies (PCCPHE)" to OMB for review under the Paperwork Reduction Act. The notice allows an additional 30 days for public comments following three comments received from the prior January 2026 notice. America's Poison Centers, a national network of 53 poison centers, serves as CDC's key partner for this surveillance initiative.
University of Pittsburgh Heat Shock Protein Modulator Patent for Huntington Disease
USPTO granted patent US12600705B2 to University of Pittsburgh for thiadiazine compounds as heat shock protein modulators. The patent covers therapeutic applications for Huntington disease, other neurodegenerative disorders, and cancer. The patent includes 13 claims.
Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof
USPTO granted patent US12600709B2 to Crinetics Pharmaceuticals covering nonpeptide somatostatin type 5 receptor agonists, methods of making the compounds, pharmaceutical compositions, and methods of using the compounds in treating conditions that benefit from somatostatin modulation. The patent includes 4 claims.
Hoffmann-La Roche Granted Amino-Pyrimidine Amide Patent US12600712B2
USPTO granted Patent US12600712B2 to Hoffmann-La Roche Inc. on April 14, 2026, covering amino-pyrimidine amide compounds with general formula (I) and methods of using such compounds. The patent includes 11 claims and CPC classifications C07D 403/06 and C07D 491/107 in organic chemistry. The filing date was December 7, 2022, with Application No. 18062644.
Hutchmed Crystalline Forms Patent Grant US12600713B2
USPTO granted patent US12600713B2 to Hutchmed Limited on April 14, 2026 for crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, a pharmaceutical compound. Inventors are Zhenping Wu, Wenji Li, and Yuping Chu. The patent contains 28 claims and was filed on February 27, 2024.
Boehringer Ingelheim Patent for sGC Activators in Systemic Sclerosis Treatment
The USPTO granted patent US12600715B2 to Boehringer Ingelheim International GmbH covering methods for treating systemic sclerosis using soluble guanylate cyclase (sGC) activators of formula (I) or their pharmaceutically acceptable salts. The patent names Mary Ruth Flack, Julia Kaufman, and Indra Sethy-Coraci as inventors and includes 20 claims spanning therapeutic applications including respiratory, dermatological, pain, and immunological indications. This method patent provides Boehringer Ingelheim with enforceable exclusivity over the specified sGC activator treatment protocol for systemic sclerosis in the United States.
Gannex Pharma FXR Modulating Compound Patent US12600716B2
USPTO granted patent US12600716B2 to Gannex Pharma Co. Ltd. on April 14, 2026, for FXR-modulating compounds having a structure of formula (I), including pharmaceutically acceptable salts, esters, and stereoisomers. The patent contains 19 claims and covers therapeutic applications including liver disease (A61P 1/16), metabolic disorders, cardiovascular conditions, and kidney disease.
US12600703B2 - Farnesyl Dibenzodiazepinone Synthesis Patent
USPTO granted patent US12600703B2 to AMO Pharma Ltd. covering methods of synthesizing farnesyl dibenzodiazepinone compounds, including AMO-01. The patent has 4 claims and was filed on May 28, 2021. Patent grants establish legally enforceable intellectual property rights for the disclosed chemical synthesis methods.
Low-Viscosity Hardener Manufacturing Method Patent
USPTO granted patent US12600706B2 to Nan Ya Plastics Corporation for a method of manufacturing low-viscosity hardener using isomerization of 3-methyltetrahydrophthalic anhydride and 4-methyltetrahydrophthalic anhydride. The patent covers a hardener crude product with a weight ratio of 3:7 to 7:3 between the two anhydrides, producing a final viscosity of 30-50 cps. The patent includes 8 claims and names Te-Chao Liao, Jung-Jen Chuang, Chung-Yu Chen, and Jung-Tsu Wu as inventors.
Cannabinoid Derivatives, Precursors and Uses - Patent US12600707B2
USPTO granted patent US12600707B2 to Kare Chemical Technologies Inc. on April 14, 2026, covering new cannabinoid derivatives, precursors, and processes for their preparation. The patent also claims pharmaceutical and analytical uses of these compounds. The patent (10 claims) protects the invention until 2040 based on the September 2020 filing date.
MDMA Prodrug Carbamate Compounds - Apoapsis Holdings
USPTO granted Patent US12600708B2 to Apoapsis Holdings, LLC for novel MDMA prodrug carbamate compounds and synthesis methods. The patent covers 19 claims for compounds that are enzymatically cleaved in vivo to produce low-toxicity alcohols. The inventors include Denton W. Hoyer, Robert F. Roscow, Rong Ling, and Chuanjun Gao.
Bioniz Therapeutics - Peptide Cytokine Inhibitors Patent Grant US12600757B2
The USPTO granted Patent US12600757B2 to Bioniz Therapeutics, Inc. on April 14, 2026. The patent covers stable peptide antagonists targeting the gamma-c (γc) subunit binding site to inhibit activity of γc-cytokine family members. The 16 claims apply to therapeutic and cosmetic agents as well as research tools for treating diseases associated with γc-family cytokines.
ENZENE BIOSCIENCES - GLP-1 Receptor Agonist Preparation Process Patent
The USPTO granted patent US12600759B2 to Enzene Biosciences Limited covering processes for preparing glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs. The patent specifically encompasses processes for preparing liraglutide, D-liraglutide, semaglutide, and D-semaglutide in substantially pure form. The application (17440127), filed on March 19, 2020, contains 4 claims and covers both solid and solution phase preparation methods.
Anti-TDP-43 Binding Molecules and Uses Thereof
The USPTO granted Patent No. US12600766B2 to AC Immune SA covering anti-TDP-43 specific binding molecules, including antibodies and antigen-binding fragments, for diagnosing, preventing, and treating diseases associated with TDP-43 aggregates. The patent lists 15 claims and names Tamara Seredenina, Tamar Magdalena Ziehm, and Tariq Afroz as inventors. The filing date was May 22, 2020, under Application No. 17613444.
ASKGENE Pharma Granted Patent for Masked Cytokines
USPTO granted Patent No. US12600762B2 to ASKGENE PHARMA, INC. on April 14, 2026. The patent covers masked cytokines (prodrugs) and methods of use for stimulating the immune system, treating cancer, autoimmune diseases, or infectious diseases. The patent contains 19 claims and was filed on January 11, 2021 under Application No. 17787741.
IBM Granted Patent for Antigen-Binding Proteins Targeting SARS-CoV-2 Variants
USPTO granted IBM (International Business Machines Corporation) Patent US12600764B2 for antigen-binding proteins capable of binding to SARS-CoV-2 coronavirus variants. The patent covers compositions comprising heavy polypeptide chain variable regions with specific amino acid substitutions (R50, I54, L55 positions) that enhance binding to CoV variants. The patent includes 14 claims and was filed on August 27, 2021.
RSV Vaccine Methods for Inactivating and Stabilizing Pre-F Protein
USPTO granted patent US12600750B2 to Xiamen University covering methods for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein. The patent also covers inactivated RSV virus obtained by the method, vaccines comprising the inactivated virus, and uses of the vaccine for preventing or treating RSV infection. The patent names six inventors including Zizheng Zheng, Wei Zhang, and Ningshao Xia, with 19 claims total.
Cobra 1/NELF-B as Booster for CD8+ T Cell-Based Therapy - US12600755B2
The USPTO granted Patent US12600755B2 to The George Washington University on April 14, 2026. The patent covers methods of generating T cells with integrated transgenes encoding negative elongation factor (NELF) complex subunits, specifically Cobra 1/NELF-B, for use in treating cancer and infectious disease. The patent contains 19 claims.
Modified S2 Subunit Coronavirus Spike Protein Patent US12600751B2
The USPTO granted patent US12600751B2 to inventors Annika Kraemer-Kuehl and Thomas Min Stephan for a modified S2 subunit of coronavirus spike protein featuring a mutation at amino acid position 865. The patent covers a recombinant avian coronavirus spike protein or fragment thereof, along with an immunogenic composition containing the modified spike protein. The patent includes 22 claims with filing date May 6, 2020.
Compstatin Analogues Patent for Complement Inhibitors
USPTO granted patent US12600749B2 to ZP SPV 3 K/S on April 14, 2026, covering compstatin analogues with improved complement-inhibiting activity. The patent includes 19 claims for peptide variants with modifications at positions 3 and 9, as well as terminal sequences, providing improved binding affinity and solubility. Inventors include Anne Pernille Tofteng Shelton, Jacob Ulrik Fog, and Jens Kvist Madsen.
Affinity Chromatography of Immunoglobulins Using Pre-capture Flocculation
USPTO granted patent US12600748B2 to RICHTER GEDEON NYRT on April 14, 2026. The patent covers methods for purifying immunoglobulins from cell culture harvest using pre-capture cleaning steps including flocculation and filtration before affinity chromatography. The invention improves eluted immunoglobulin quality, reduces precipitation during chromatography, and extends the lifetime of affinity resin used in large-scale immunoglobulin production.
Native Chemical Ligation Flow Synthesis - University of Sydney
The USPTO granted Patent US12600746B2 to the University of Sydney covering synthetic methods using native chemical ligation in flow for synthesizing polypeptides. The patent, invented by Richard J. Payne and Tim Chisholm, includes 27 claims and covers selective desulfurization or deselenization of amide-containing compounds with thiol, disulfide, selenol, or diselenide functional groups. The patent application was filed on May 22, 2019, under application number 17057069.
Bioactive Polypeptides for Plant Protection, Growth and Productivity
USPTO granted Patent US12599649B2 to Spogen Biotech Inc. covering bioactive priming polypeptides for agricultural applications. The patent protects formulations containing 7 claims that enhance plant growth, yield, health, longevity, productivity, and vigor, while reducing abiotic stress and providing protection from disease, insects, and nematodes. The patent was filed on July 20, 2018.
Veterinary Formulations Comprising Rapamycin and Methods of Using the Same for Treating Animal Disease
The USPTO granted Patent US12599590B2 to TriviumVet DAC covering veterinary formulations comprising rapamycin or rapalogs for treating animal diseases including cardiac dysfunction, hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, cancer, effects of aging, inflammatory disease, and viral infection in companion animals. The patent contains 15 claims and was filed on December 18, 2020.
Timolol Compositions for Glaucoma Treatment, Novaliq
USPTO granted patent US12599607B2 to Novaliq GmbH on April 14, 2026, covering pharmaceutical compositions comprising timolol (a β1-receptor blocker) combined with a semifluorinated alkane liquid vehicle for topical ophthalmic administration. The patented compositions are intended for treatment of glaucoma, elevated intraocular pressure, ocular hypertension, and associated symptoms. The patent contains 21 allowed claims.
PDE1 Inhibitors Treat Colon Cancer, USPTO Grant
The USPTO granted Patent US12599603B2 to Intra-Cellular Therapies, Inc. covering phosphodiesterase 1 (PDE1) inhibitors for the treatment of colon cancer and certain tumors. The patent, with inventors Peng Li and Robert Davis, claims 12 method-of-treatment claims. The application was filed on September 3, 2020.
2-AG Enhancing Compositions for Migraine Relief
The USPTO granted Patent US12599600B2 to Arizona Board of Regents on Behalf of the University of Arizona for compositions and methods enhancing 2-arachydonyl glycerol (2AG) activity to prevent and treat headaches, particularly migraines. The patent covers methods for reducing prostaglandin activity and includes claims for pharmaceutical compositions containing 2AG-enhancing compounds.
MEDICON Anti-inflammatory, Anti-cancer, and Anti-angiogenic Compounds Patent
The USPTO granted patent US12599599B2 to MEDICON PHARMACEUTICALS, INC. covering compounds of general Formula A-D-Y with anti-inflammatory, anti-cancer, and anti-angiogenic activity for treating inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. The patent includes pharmaceutical compositions, methods of making, and methods of use with 4 claims.
N-Benzhydrylacetamide Inhibitors of Jumanji Domain Histone Demethylases for Cancer Treatment
USPTO granted patent US12599597B2 to the University of Kentucky Research Foundation covering substituted N-benzhydrylacetamide inhibitors of Jumanji domain histone demethylases for treating cancer via Wnt signaling pathway inhibition. The patent includes 10 claims and covers compounds according to Formula I and II, along with methods of administering these compounds to subjects needing cancer treatment.
Vemurafenib Salts for Enteroviral Infection Treatment (US12599591B2)
USPTO granted Patent US12599591B2 to Jyväskylän yliopisto for N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (vemurafenib) and pharmaceutical salts for treating enteroviral diseases. The patent contains 14 claims and is classified under CPC codes A61K 31/437 and A61P 31/16.
Succinimide Anticonvulsants Treat Expressive Language Deficit in Autism
USPTO granted patent US12599581B2 to AMS Therapeutics covering a pharmacological method for treating expressive language deficit in autistic humans using succinimide anticonvulsants (ethosuximide, methsuximide, phensuximide). The patent contains 10 claims with application number 18621580 filed on March 29, 2024.
Pharmaceutical Compositions with NSAID and Fatty Acid Oxidase Inhibitor for Treating Infections, Inflammation, Aging
The USPTO granted patent US12599614B2 to MD VAULT LLC for pharmaceutical compositions combining non-steroidal anti-inflammatory drugs (NSAIDs) with fatty acid oxidation inhibitors for treating microbial infectious diseases, associated inflammatory disorders, and aging-related conditions. The patent, filed December 13, 2021, contains 9 claims and covers compositions including agents such as diclofenac (A61K 31/616), mefenamic acid (A61K 31/495), and phenylbutazone (A61K 31/192).
Methods of Treating Fuchs Endothelial Corneal Dystrophy After Descemetorhexis
USPTO granted patent US12599609B2 to Kowa Company, Ltd. for methods of treating Fuchs endothelial corneal dystrophy (FECD) following descemetorhexis. The patent covers medications promoting healing in FECD patients and contains 26 claims. The inventors are Gary Gordon and Kazuhito Suehira.
Methods for Treating Cardiac Valve Disease Using Pharmaceutical Compounds
The USPTO granted Patent US12599608B2 to The Regents of the University of California covering methods of treating cardiac valve disease, including calcific aortic valve disease (CAVD), by administering pharmaceutical compounds of Formulae I-X. The patent names Christina Theodoris and Deepak Srivastava as inventors and includes 4 claims covering therapeutic applications and compound identification methods.
Roche Diagnostics Imidazolium Reagent Mass Spectrometry Patent Grant
The USPTO granted Patent US12600700B2 to Roche Diagnostics Operations, Inc. covering imidazolium compounds and methods for mass spectrometric determination of analyte molecules. The patent, applied for in November 2022 under application number 17991282, was granted with 14 claims. The invention relates to compounds suitable for use in mass spectrometry and associated analytical methods.
Thiosemicarbazates and Uses Thereof - US12600699B2
The USPTO granted Patent US12600699B2 to The Feinstein Institutes for Medical Research covering thiosemicarbazates, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides. The patent also protects a chemoselective functionalization protocol using Mitsunobu reaction for site-specific alkylation. Methods for preparing and using these compounds in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are included in the 17 granted claims.
N-Acylhydrazonic Compounds Treat Amyloid Diseases, Patent Grant
USPTO granted patent US12600701B2 to Faculdades Católicas for N-acylhydrazonic compounds structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde for preventing and treating amyloid degenerative aggregopathies including Alzheimer's disease, Parkinson's disease, and type 2 diabetes, as well as non-amyloid conditions such as cataracts. The patent covers four specific compounds and pharmaceutical compositions containing them.
Crystalline Forms of Quinazolinyl-Benzonitrile Compound and Ocular Formulations
USPTO granted patent US12600702B2 to Bausch + Lomb Ireland Limited for crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof. The patent covers methods for treating ocular surface pain, dry eye disease, and ocular hyperemia. The application was filed on February 13, 2020 under application number 17430819, with 16 claims granted.
Kinase Inhibitors Patent - VIDYA Therapeutics, Inc.
USPTO granted Patent US12600698B2 to VIDYA Therapeutics, Inc. on April 14, 2026. The patent covers Bruton tyrosine kinase (BTK) inhibitors designed to penetrate the central nervous system, including pharmaceutical compositions and methods of treatment. The patent includes 21 claims with an August 2022 filing date.
Compositions and Methods for Removal of NMP Degradation Products from NMP Purification Systems
USPTO granted patent US12600697B2 to Refined Technologies, Inc. covering methods for cleaning N-methyl-2-pyrrolidone (NMP) purification and recovery systems. The patent claims compositions and methods using a cleaning solution containing a solvent with a primary amine and hydroxyl group, injected into reflux drums and reboilers, circulated through separation towers to solubilize foulants, then drained. The patent was filed May 25, 2022, and contains 15 claims under CPC classifications C07D 207/267 and C07D 201/16.
Markers, Conjugates, Compositions and Methods for Hypoxia Imaging, Mapping, and Therapy
USPTO granted patent US12600742B2 to WWIKY Biosciences Inc. on April 14, 2026. The patent covers markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy using bio-reductively activated compounds with click chemistry. Inventors include Piyush Kumar, Hassan Elsaidi, Leonard Irving Wiebe, and Michael Weinfeld. The patent includes 5 claims.
Multivalent Peptide Conjugates for Intra-Articular Joint Inflammation Treatment
USPTO granted patent US12599663B2 to VALITOR, INC. on April 14, 2026. The patent covers multivalent peptide-polymer conjugates designed for sustained intra-articular treatment of joint inflammation, with 23 claims.
Serum Albumin-Binding Fibronectin Type III Domains and Therapeutic Applications
USPTO granted Patent US12599652B2 to Janssen Biotech, Inc. covering fibronectin type III (FN3) domains that specifically bind to serum albumin. The patented technology includes related polynucleotides, cells expressing FN3 domains, and FN3 domains fused to heterologous moieties. The invention is designed to extend half-life of molecules in diagnostic and therapeutic applications.
ADAMTS-7 Metalloprotease Peptide Vaccine for Anti-Atherosclerosis - Beijing Kimway
The USPTO granted patent US12599654B2 to Beijing Kimway Biotech Co. Ltd. covering immunogenic peptide fragments of metalloprotease ADAMTS-7 and their use in anti-atherosclerosis vaccines. The patent, granted April 14, 2026 with an original filing date of August 20, 2020, includes 3 claims covering short peptide sequences (SEQ ID NO: 1-4) and vaccine compositions designed to inhibit vascular restenosis and atherosclerosis in mouse models.
Indoline Derivatives for Disease Treatment
The USPTO granted patent US12599584B2 to Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. covering indoline derivatives and pharmaceutical compositions for treating diseases associated with oxidative stress, immune response, NO release, and pro-inflammatory cytokines. The patent names Marta Weinstock-Rosin, Abraham Nudelman, and Shani Zeeli as inventors and was filed on January 19, 2017. This grant establishes intellectual property protection for the therapeutic applications of these indoline compounds.
Cenobamate Carbamate Combination Therapy Patent for Epilepsy Treatment
USPTO granted patent US12599585B2 to SK Biopharmaceuticals covering combination therapy using cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate with antiepileptic drugs for preventing or treating neurological disorders such as epilepsy. The patent contains 5 claims and lists inventors Marc Kamin and Laurent Vernillet.
Biphenyl Derivative Antimicrobial Adjuvant Patent Granted
USPTO granted Patent US12599575B2 to Korea Research Institute of Bioscience and Biotechnology for an antimicrobial adjuvant containing biphenyl derivative compounds as active ingredients. The patent covers technology that enhances sensitivity of gram-negative bacteria to polymyxin antibiotics, potentially reducing required dosages and associated side effects such as nephrotoxicity. The patent includes 14 claims and was filed on January 28, 2022 under Application No. 18275475.
Japan Science and Technology Agency V-ATPase Inhibitor Patent
USPTO granted patent US12599588B2 to Japan Science and Technology Agency for an inhibitor of Na+-translocating V-ATPase activity. The compound serves as an antibacterial agent and medicine with applications in antibacterial and screening methods. The patent application was filed January 15, 2020, contains 12 claims, and covers compounds with specific structural features including hydroxy, alkoxy, and amino substituents on phenyl groups.
Chlorinated Tetralin Compounds and Pharmaceutical Compositions
USPTO granted patent US12599587B2 to Springworks Therapeutics, Inc. on April 14, 2026. The patent covers chlorinated tetralin compounds and pharmaceutical compositions, classified under C07D 233/88 and A61K 31/417. The application (No. 18490993) was filed on October 20, 2023, and the granted patent contains 19 claims.
Bayer Aktiengesellschaft Substituted Isophthalic Acid Diamides Herbicide Patent, US12599136B2
The USPTO granted Patent US12599136B2 to Bayer Aktiengesellschaft covering substituted isophthalic acid diamides of general formula (I) for use as herbicides. The patent includes 15 claims covering compounds where X and Y are hydrogen, alkyl, or halogen radicals, and Z1 and Z2 are alkyl, cycloalkyl, or phenyl radicals with a heterocyclic Q ring. The patent was filed April 1, 2021, under Application No. 17995662.
Pyrrole Compounds Patent - Aligos Therapeutics - US12599582B2
USPTO granted Patent US12599582B2 to Aligos Therapeutics covering pyrrole compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods of treating diseases and conditions. The patent names inventors Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, and Vladimir Serebryany. The application was filed August 22, 2023, with 2 claims granted.
FDA DMB Acknowledgment Letter to Hyman Phelps McNamara
FDA Division of Manufacturing and Quality (DMB) within CDER sent an acknowledgment letter to Hyman, Phelps & McNamara, P.C. in response to submission FDA-2026-P-4018. The acknowledgment indicates receipt of the submission without substantive review or determination at this stage. No regulatory obligations, compliance deadlines, or enforcement actions are imposed by this document.
Center for Tobacco Products Complaint, Apr 13, 2026
FDA Center for Tobacco Products (CTP) filed a complaint on April 13, 2026. The document is classified as closed in the Regulations.gov system (Docket FDA-2026-H-3804). The full complaint text is not available for public viewing on the regulatory portal. This appears to be a formal complaint related to tobacco product regulation.
BILTRICIDE Not Withdrawn for Safety or Effectiveness
FDA has determined under 21 CFR 314.161 that BILTRICIDE (praziquantel) oral tablet, 600 mg, was not withdrawn from sale for reasons of safety or effectiveness. The drug product, which was discontinued by Bayer Healthcare Pharmaceuticals in February 2024 and moved to the Orange Book's Discontinued Drug Product List, retains its eligibility for ANDA approvals. Novitium Pharma LLC submitted a citizen petition requesting this determination, which FDA granted based on review of Agency records.
Suitability Petition to FDA
Hyman, Phelps & McNamara, P.C. filed a Suitability Petition with the FDA under docket FDA-2026-P-4020-0001. The petition appears to request FDA approval for a drug product change under applicable administrative procedures. The filing was submitted to CDER for review.
FDA Suitability Petition, Comment Period Open
FDA Suitability Petition, Comment Period Open
FDA Reminds 2,200 Sponsors to Disclose Trial Results
The FDA sent messages on March 30, 2026, to more than 2,200 companies and researchers associated with over 3,000 registered clinical trials that do not appear to have submitted required results information to ClinicalTrials.gov. The agency seeks voluntary compliance before considering further regulatory action, including potential Pre-Notices and Notices of Noncompliance.
Controlled Movement Method for Gametes, Zygotes, Embryos
USPTO published patent application US20260098250A1 assigned to CIC nanoGUNE, filed September 6, 2023, covering a method and device for controlled movement of gametes, zygotes, and embryos using micro-scale carriers. The device comprises biocompatible carriers with maximum 500 μm dimensions that can releasably connect to biological cells and move autonomously or via external influences. The technology aims to enable less invasive procedures and higher implantation rates in reproductive medicine and healthcare applications.
G47ΔhIL12A Oncolytic HSV for Glioblastoma and Triple-Negative Breast Cancer Treatment
USPTO published patent application US20260097135A1 for G47ΔhIL12A, an oncolytic herpes simplex virus (oHSV) engineered with human IL-12 transgene driven by HCMV IE enhancer/promoter. The invention addresses augmented transgene production and increased virus replication while maintaining safety profiles. Applications include treatment of glioblastoma (GBM) and triple-negative breast cancer (TNBC). Filing date: September 26, 2023; Application No. 19114912.
Biallelic Knockout CISH Gene, RNA Compositions
USPTO published patent application US20260097121A1 by inventor Rafi Emmanuel covering RNA compositions with guide sequences targeting the CISH gene for biallelic knockout. The application includes sequences defined by SEQ ID NOs 1-6838 and methods for their use. Filing date was September 18, 2023, under application number 19113098.
Biallelic CIITA Knockout Patent, 34199 RNA Sequences
USPTO published patent application US20260097123A1 for compositions and methods for biallelic CIITA knockout using RNA molecules comprising guide sequences of 17-50 nucleotides. The application covers 34,199 sequences (SEQ ID NOs 1-34199). Inventor: Rafi Emmanuel. Filing date: September 19, 2023.
Patent for RSV vaccine using F protein trimer prefusion conformation
Patent for RSV vaccine using F protein trimer prefusion conformation
Phio Pharmaceuticals T Cell Induction Method for Cancer Treatment
USPTO published patent application US20260097120A1 assigned to Phio Pharmaceuticals Corp. The application covers methods for producing immunogenic compositions using ex vivo T cell treatment with oligonucleotide agents capable of controlling T cell differentiation through PD-1 silencing via chemically modified double-stranded nucleic acid molecules. The disclosed compositions and methods target cancer treatment, including melanoma.
Solid-State Storage of Biochemical Systems Patent Application
USPTO published patent application US20260098247A1 by inventor Javin Oza disclosing compositions and methods for solid-state storage of biological systems using polymeric cryoprotectants, saccharide cryoprotectants, emulsifiers, and lubricating flow agents, enabling cold chain-free, point-of-care platforms for diagnostics, research, biomanufacturing, and testing.
Ureteric Bud Kidney Tissue Engineering Compositions and Methods
The USPTO published patent application US20260098246A1 disclosing engineered ureteric bud kidney tissues and methods for making lumenized kidney tissues with spatially-controlled 3D tubular architecture. The application includes in vitro kidneys comprising nephron progenitor cells and ureteric bud cells. Inventors: Benjamin Shepherd, Alice Chen, J. William Higgins, III. Filed July 30, 2025.
Stem Cell Differentiation Method for Progenitor Cells and Organoids
The USPTO published patent application US20260098245A1 assigned to Koninklijke Nederlandse Akademie Van Wetenschappen (Royal Netherlands Academy of Arts and Sciences). The application, filed December 10, 2025, covers differentiation methods for progenitor cells including mammalian epithelial stem cells, differentiation media compositions for use in said methods, organoids and cells obtainable by said methods, and therapeutic uses thereof. Inventors are Johannes Carolus Clevers and Helmuth Gehart.
Novozymes A/S Patent for Enzymatic Plant Protein Extract Method
USPTO published patent application US20260096575A1 assigned to Novozymes A/S for an enzymatic method of producing plant protein extract. The method involves treating plant protein raw materials under alkaline conditions with protein deamidase added before, during, or after treatment, followed by protein recovery and spray drying. The resulting plant protein extract has improved solubility suitable for food or beverage applications. The application was filed on September 28, 2023.
Ultra-High Molecular Weight Xanthan Gum Engineered Strain and Detection Marker
The USPTO published patent application US20260098104A1 for an engineered bacterial strain that produces ultra-high molecular weight xanthan gum with molecular weight exceeding 2.0×10^7 Da, significantly above the ordinary range of 0.2×10^7-2.0×10^7 Da. The application also discloses a molecular marker for detecting the engineered strain and its processed products, enabling rapid identification in production and quality control contexts.
Dura Mater-Derived Stem Cells and Method for Producing the Same
USPTO published patent application US20260098243A1 for dura mater-derived stem cells and production methods. Inventors: Sun Hwa PARK, Sung Won KIM, Seung Ho YANG, Jung Eun LEE, Hyun Ji LEE. The application, filed 2025-10-06 under Application No. 19350367, covers methods of isolating stem cells from dura mater with serum supplements and their use in cell therapeutic agents.
Harvard Patent - Automated Parallel Chromatography for Extracellular Vesicle Purification
USPTO published patent application US20260098244A1 from President and Fellows of Harvard College disclosing devices and methods for automated parallel chromatography for purification of extracellular vesicles from biological samples. The invention includes a pump, computing device, and a stand with columns containing resin and bottom wells or tubes. CPC classifications indicate applications in cell/vesicle technology and chromatography methods.
Methods for Producing Highly Purified (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate for Enhancing Bodily Function and Treating Disease States
USPTO published patent application US20260098281A1 by Romeo Tango, LLC for methods of producing highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and biomedical uses thereof. The application covers therapeutic applications including inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additional applications include improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection.
Lipid-Encapsulated Dual-Cleaving Endonuclease for DNA and Gene Editing
USPTO published patent application US20260098248A1 for a lipid-encapsulated dual-cleaving endonuclease enabling non-viral gene editing methods, filed October 10, 2025 under application number 19355897. Inventors include David R. Edgell, Thomas A. McMurrough, Brent E. Stead, and Odisho K. Israel. The invention covers methods of administering a chimeric nuclease to cells or organisms without viral vectors.